PTK2 and small cell lung carcinoma: These variants are associated with poor prognosis, exhibit elevated tyrosine kinase activity and are sensitive to FAK inhibitors, representing high-frequency gain-of-function alterations in oncogenes and potential therapeutic targets for SCLC.